BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK
Primary Care and Public Health, Imperial College London, London, UK.
BMJ Open. 2023 Nov 22;13(11):e071072. doi: 10.1136/bmjopen-2022-071072.
Determine the prevaccination healthcare impact of COVID-19 in patients with systemic lupus erythematosus (SLE) in England.
Retrospective cohort study of adult patients with SLE from 1 May to 31 October 2020.
Clinical Practice Research Datalink (CPRD) Aurum and Hospital Episode Statistics (HES) databases from general practitioners across England combining primary care and other health-related data.
Overall, 6145 adults with confirmed SLE diagnosis ≥1 year prior to 1 May 2020 were included. Most patients were women (91.0%), white (67.1%), and diagnosed with SLE at age <50 (70.8%). Patients were excluded if they had a COVID-19 diagnosis before 1 May 2020.
Demographics and clinical characteristics were compared. COVID-19 severity was determined by patient care required and procedure/diagnosis codes. COVID-19 cumulative incidence, hospitalisation rates, lengths of stay and mortality rates were determined and stratified by SLE and COVID-19 severity.
Of 6145 patients, 3927 had mild, 1288 moderate and 930 severe SLE at baseline. The majority of patients with moderate to severe SLE were on oral corticosteroids and antimalarial treatments. Overall, 54/6145 (0.88%) patients with SLE acquired and were diagnosed with COVID-19, with 45 classified as mild, 6 moderate and 3 severe COVID-19. Cumulative incidence was higher in patients with severe SLE (1.4%) compared with patients classified as mild (0.8%) or moderate (0.8%). Ten COVID-19-specific hospital admissions occurred (n=6 moderate; n=4 severe). Regardless of COVID-19 status, hospital admission rates and length of stay increased with SLE severity. Of 54 patients with SLE diagnosed with COVID-19, 1 (1.9%) COVID-19-related death was recorded in a patient with both severe SLE and severe COVID-19.
SLE severity did not appear to impact COVID-19 outcomes in this study. The COVID-19 pandemic is evolving and follow-up studies are needed to understand the relationship between COVID-19 and SLE.
确定英格兰系统性红斑狼疮(SLE)患者 COVID-19 疫苗接种前的医疗保健影响。
2020 年 5 月 1 日至 10 月 31 日期间,对来自英国全科医生的临床实践研究数据链接(CPRD)Aurum 和医院病例统计(HES)数据库中成人 SLE 患者进行回顾性队列研究。
该研究将来自英国各地全科医生的临床实践研究数据链接(CPRD)Aurum 和医院病例统计(HES)数据库相结合,纳入了初级保健和其他健康相关数据。
总体而言,纳入了 6145 名确诊 SLE 诊断≥1 年的成年人。大多数患者为女性(91.0%),白人(67.1%),SLE 发病年龄<50 岁(70.8%)。如果患者在 2020 年 5 月 1 日之前有 COVID-19 诊断,则将其排除在外。
比较了人口统计学和临床特征。根据患者所需的护理和程序/诊断代码确定 COVID-19 严重程度。确定了 COVID-19 的累积发病率、住院率、住院时间和死亡率,并根据 SLE 和 COVID-19 的严重程度进行分层。
在 6145 名患者中,3927 名患者 SLE 为轻度,1288 名患者 SLE 为中度,930 名患者 SLE 为重度。大多数中重度 SLE 患者接受口服皮质类固醇和抗疟药物治疗。总体而言,6145 名 SLE 患者中有 54 名(0.88%)感染并被诊断出患有 COVID-19,其中 45 名被归类为轻度,6 名被归类为中度,3 名被归类为重度 COVID-19。重度 SLE 患者的累积发病率(1.4%)高于轻度 SLE 患者(0.8%)或中度 SLE 患者(0.8%)。有 10 例 COVID-19 特异性住院治疗(中度 6 例;重度 4 例)。无论 COVID-19 状态如何,住院率和住院时间均随 SLE 严重程度的增加而增加。在 54 名确诊为 COVID-19 的 SLE 患者中,1 名(1.9%)同时患有重度 SLE 和重度 COVID-19 的患者记录了与 COVID-19 相关的死亡。
在这项研究中,SLE 的严重程度似乎并未影响 COVID-19 的结局。COVID-19 大流行正在演变,需要进一步的研究来了解 COVID-19 和 SLE 之间的关系。